Opportunities in U.S. Equities
Contingent Income Auto-Callable Securities due
July 28, 2022, with 6-month Initial Non-Call Period
Observation Dates, Redemption
Determination Dates, Coupon Payment Dates and Early Redemption Dates
Contingent Income Auto-Callable Securities due July 28, 2022,
with 6-month Initial Non-Call Period All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health
Corporation, the Common Stock of McDonald
’
s Corporation, the
Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company (the “securities”) do not provide
for the regular payment of interest. Instead, the securities will pay a contingent monthly coupon at an annual rate of 9.00%
but
only if
the determination closing price of
each underlying stock
is
at or above
57.75% of its respective initial
share price, which we refer to as the respective downside threshold level, on the related observation date. If the determination
closing price of
any underlying stock
is less than its downside threshold level on any observation date, we will pay no
coupon for the related monthly period.
However, if the determination closing
price of each of the underlying stocks is at or above its respective downside threshold level on any subsequent observation date,
investors will receive, in addition to the contingent monthly coupon for the related monthly period, any previously unpaid contingent
monthly coupons from prior observation dates.
It is possible that the determination closing price of
one or more underlying
stocks will remain below their respective downside threshold levels
for extended periods of time or even throughout the entire
3-year term of the securities so that you will receive few or no contingent monthly coupons during the entire term of the securities.
We refer to these coupons as contingent, because there is no guarantee that you will receive a coupon payment on any coupon payment
date. Even if all of the underlying stocks were to be at or above their respective downside threshold levels on some monthly observation
dates, one or more underlying stocks may fluctuate below the respective downside threshold level(s) on others, and the underlying
stocks may not close at or above their respective downside threshold level on any subsequent observation date, in which case you
will not receive payment of any unpaid previously contingent monthly coupons. In addition, if the securities have not been automatically
called prior to maturity and the final share price of
any underlying stock
is less than its respective downside threshold
level, investors will be exposed to the decline in the worst performing underlying stock on a 1-to-1 basis, and will receive a
payment at maturity that is less than 57.75% of the stated principal amount of the securities and could be zero.
Accordingly,
i
nvestors in the securities must be willing to accept the risk of losing their entire initial investment and also the risk of
not receiving any contingent monthly payments throughout the entire 3-year term of the securities.
The original issue price of each security is
$1,000. This price includes costs associated with issuing, selling, structuring and hedging the securities, which are borne by
you, and, consequently, the estimated value of the securities on the pricing date will be less than $1,000. We estimate that the
value of each security on the pricing date will be approximately $951.40, or within $22.50 of that estimate. Our estimate of the
value of the securities as determined on the pricing date will be set forth in the final pricing supplement.
In valuing the securities on the pricing date,
we take into account that the securities comprise both a debt component and a performance-based component linked to the underlying
stocks. The estimated value of the securities is determined using our own pricing and valuation models, market inputs and assumptions
relating to the underlying stocks, instruments based on the underlying stocks, volatility and other factors including current and
expected interest rates, as well as an interest rate related to our secondary market credit spread, which is the implied interest
rate at which our conventional fixed rate debt trades in the secondary market.
In determining the economic terms of the securities,
including the contingent monthly coupon rate, the redemption threshold levels and the downside threshold levels, we use an internal
funding rate, which is likely to be lower than our secondary market credit spreads and therefore advantageous to us. If the issuing,
selling, structuring and hedging costs borne by you were lower or if the internal funding rate were higher, one or more terms of
the securities would be more favorable to you.
The price at which MS & Co. purchases the
securities in the secondary market, absent changes in market conditions, including those related to the underlying stocks, may
vary from, and be lower than, the estimated value on the pricing date, because the secondary market price takes into account our
secondary market credit spread as well as the bid-offer spread that MS & Co. would charge in a secondary market transaction
of this type and other factors. However, because the costs associated with issuing, selling, structuring and hedging the securities
are not fully deducted upon issuance, for a period of up to 6 months following the issue date, to the extent that MS & Co.
may buy or sell the securities in the secondary market, absent changes in market conditions, including those related to the underlying
stocks, and to our secondary market credit spreads, it would do so based on values higher than the estimated value. We expect that
those higher values will also be reflected in your brokerage account statements.
MS & Co. may, but is not obligated to,
make a market in the securities, and, if it once chooses to make a market, may cease doing so at any time.
The securities do not provide for the regular payment of interest.
Instead, the securities will pay a contingent monthly coupon
but only if
the determination closing price of
each underlying
stock
is
at or above
its respective downside threshold level on the related observation date. The securities have been
designed for investors who are willing to forgo market floating interest rates and risk the loss of principal and accept the risk
of receiving few or no coupon payments for the entire 3-year term of the securities in exchange for an opportunity to earn interest
at a potentially above-market rate if all of the underlying stocks close at or above their respective downside threshold levels,
unless the securities are redeemed early. The following scenarios are for illustration purposes only to demonstrate how the coupon
and the payment at maturity (if the securities have not previously been redeemed) are calculated, and do not attempt to demonstrate
every situation that may occur. Accordingly, the securities may or may not be redeemed, the contingent coupon may be payable in
none of, or some but not all of, the monthly periods during the 3-year term of the securities, and the payment at maturity may
be less than 57.75% of the stated principal amount of the securities and may be zero.
The following diagrams illustrate the potential outcomes for
the securities depending on (1) the determination closing prices on each monthly observation date, (2) the determination closing
prices on each monthly redemption determination date and (3) the final share prices. Please see “Hypothetical Examples”
below for an illustration of hypothetical payouts on the securities.
Diagram #1: Contingent Monthly Coupons (Beginning
on the First Coupon Payment Date until Early Redemption or Maturity)
The following hypothetical examples illustrate how to determine
whether a contingent monthly coupon is paid with respect to an observation date and how to calculate the payment at maturity, if
any, assuming the securities are not redeemed prior to maturity. The following examples are for illustrative purposes only. Whether
you receive a contingent monthly coupon will be determined by reference to the determination closing price of each underlying stock
on each monthly observation date. Whether the securities are redeemed early will be determined by reference to the determination
closing price of each underlying stock on each monthly determination date (beginning approximately six months after the original
issue date) and the payment at maturity, if any, will be determined by reference to the final share price of each underlying stock
on the final determination date. The actual initial share price and downside threshold level for each underlying stock will be
determined on the pricing date. All payments on the securities, if any, are subject to our credit risk. The below examples are
based on the following terms:
How to determine whether a contingent monthly
coupon is payable with respect to an observation date:
On hypothetical observation date 1, each of the underlying stocks
closes at or above its respective downside threshold level. Therefore, a hypothetical contingent monthly coupon of $7.50 is paid
on the relevant coupon payment date.
On hypothetical observation date 2, three underlying stocks close
at or above their respective downside threshold levels, but the other underlying stock closes below its respective downside threshold
level. Therefore, no contingent monthly coupon is paid on the relevant coupon payment date.
On hypothetical observation date 3, each of the underlying stocks
closes at or above its respective downside threshold level. Therefore, investors receive the hypothetical contingent monthly coupon
with respect to the third observation date as well as the previously unpaid contingent monthly coupon with respect to the second
observation date.
On hypothetical observation date 4, each of the underlying stocks
closes below its respective downside threshold level, and accordingly no contingent monthly coupon is paid on the relevant coupon
payment date.
In the following examples, one or more underlying stocks close
below the respective redemption threshold levels on each redemption determination date, and, consequently, the securities are not
automatically redeemed prior to, and remain outstanding until, maturity.
|
Final Share Price
|
Payment at Maturity
|
|
CVS Stock
|
MCD Stock
|
JNJ Stock
|
DIS Stock
|
|
Example 1:
|
$80.00 (
at or above
its downside threshold level)
|
$240.00 (
at or above
its downside threshold level)
|
$175.00 (
at or above
its downside threshold level)
|
$190.00 (
at or above
its downside threshold level)
|
$1,000
plus
the contingent monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from the prior observation dates
|
Example 2:
|
$12.00 (
below
its downside threshold level)
|
$190.00 (
at or above
its downside threshold level)
|
$100.00 (
at or above
its downside threshold level)
|
$105.00 (
at or above
its downside threshold level)
|
$1,000 x share performance factor of the worst performing underlying stock = $1,000 x ($12.00 / $60.00) = $200.00
|
Example 3:
|
$42.00 (
at or above
its downside threshold level)
|
$175.00 (
at or above
its downside threshold level)
|
$63.00 (
below
its downside threshold level)
|
$113.00 (
at or above
its downside threshold level)
|
$1,000 x ($63.00 / $140.00) = $450.00
|
Example 4:
|
$24.00 (
below
its downside threshold level)
|
$96.75 (
below
its downside threshold level)
|
$61.60 (
below
its downside threshold level)
|
$79.75 (
below
its downside threshold level)
|
$1,000 x ($24.00 / $60.00) = $400.00
|
Example 5:
|
$27.00 (
below
its downside threshold level)
|
$64.50 (
below
its downside threshold level)
|
$63.00 (
below
its downside threshold level)
|
$63.80 (
below
its downside threshold level)
|
$1,000 x ($64.50 / $215.00) = $300.00
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
In example 1, the final share prices of each of the CVS Stock,
MCD Stock, JNJ Stock and DIS Stock are at or above their respective downside threshold levels. Therefore, investors receive at
maturity the stated principal amount of the securities
plus
the hypothetical contingent monthly coupon with respect to the
final observation date and any previously unpaid contingent monthly coupons from the prior observation dates. Investors do not
participate in the appreciation of any of the underlying stocks.
In example 2, the final share prices of three underlying stocks
are above their respective downside threshold levels, but the final share price of the other underlying stock is below its downside
threshold level. Therefore, investors are exposed to the downside performance of the worst performing underlying stock at maturity
and receive an amount equal to the stated principal amount
times
the share performance factor of the worst performing underlying
stock.
In example 3, the final share prices of three underlying stocks
are at or above their respective downside threshold levels, but the final share price of the other underlying stock is below its
downside threshold level. Therefore, investors are exposed to the downside performance of the worst performing underlying stock
at maturity and receive at maturity an amount equal to the stated principal amount times the share performance factor of the worst
performing underlying stock.
In examples 4 and 5, the final share prices of all of the underlying
stocks are below their respective downside threshold levels, and investors receive at maturity an amount equal to the stated principal
amount
times
the share performance factor of the worst performing underlying stock. In example 4, the CVS Stock has declined
60% from its initial share price to its final share price, the MCD Stock has declined 55% from its initial share price to its final
share price, the JNJ Stock has declined 56% from its initial share price to its final share price and the DIS Stock has declined
45% from its initial share price to its final share price. Therefore, the payment at maturity equals the stated principal amount
times
the share performance factor of the CVS Stock, which represents the worst performing underlying stock in this example.
In example 5, the CVS Stock has declined 55% from its initial share price to its final share price, the MCD Stock has declined
70% from its initial share price to its final share price, the JNJ Stock has declined 55% from its initial share price to its final
share price and the DIS Stock has declined 56% from its initial share price to its final share price. Therefore the payment at
maturity equals the stated principal amount
times
the share performance factor of the MCD Stock, which represents the worst
performing underlying stock in this example.
If the final share price of ANY underlying stock is below
its respective downside threshold level, you will be exposed to the downside performance of the worst performing underlying stock
at maturity, and your payment at maturity will be less than 57.75% of the stated principal amount per security and could be zero.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Risk Factors
The
following is a list of certain key risk factors for investors in the securities. For further discussion of these and other risks,
you should read the section entitled “Risk Factors” in the accompanying product supplement and prospectus. You should
also consult with your investment, legal, tax, accounting and other advisers
in connection with your investment in
the securities
.
|
§
|
The securities do not guarantee the return of any principal.
The
terms of the securities differ from those of ordinary debt securities in that they do not guarantee the return of any of the principal
amount at maturity. If the securities have not been automatically redeemed prior to maturity and if the final share price of
any
underlying stock is less than its downside threshold level of 57.75% of its initial share price, you will be exposed to the decline
in the closing price of the worst performing underlying stock, as compared to its initial share price, on a 1-to-1 basis, and you
will receive for each security that you hold at maturity an amount equal to the stated principal amount
times
the share
performance factor of the worst performing underlying stock. In this case, the payment at maturity will be less than 57.75% of
the stated principal amount and could be zero.
You could lose up to your entire investment in the securities.
|
|
§
|
The securities do not provide for the regular payment of interest
and may pay no interest over the entire term of the securities.
The terms of the securities differ from those of ordinary
debt securities in that they do not provide for the regular payment of interest. Instead, the securities will pay a contingent
monthly coupon but only if the determination closing price of each underlying stock is at or above 57.75% of its respective initial
share price, which we refer to as the respective downside threshold level, on the related observation date. If the determination
closing price of any underlying stock is lower than its downside threshold level on the relevant observation date for any interest
period, we will pay no coupon on the applicable coupon payment date. However, if the determination closing price of each of the
underlying stocks is at or above its respective downside threshold level on any subsequent observation date, investors will receive,
in addition to the contingent monthly coupon for the related monthly period, any previously unpaid contingent monthly coupons from
prior observation dates. Nevertheless, it is possible that the determination closing price(s) of one or more underlying stocks
could remain below the respective downside threshold level(s) for extended periods of time or even throughout the entire 3-year
term of the securities so that you will receive few or no contingent monthly coupons. If you do not earn sufficient contingent
coupons over the term of the securities, the overall return on the securities may be less than the amount that would be paid on
a conventional debt security of ours of comparable maturity.
|
|
§
|
You are exposed to the price risk of all of the underlying stocks,
with respect to both the contingent monthly coupons, if any, and the payment at maturity, if any.
Your
return on the securities is not linked to a basket consisting of the underlying stocks. Rather, it will be contingent upon the
independent performance of each underlying stock. Unlike an instrument with a return linked to a basket of underlying assets, in
which risk is mitigated and diversified among all the components of the basket, you will be exposed to the risks related to each
of the underlying stocks. Poor performance by
any
underlying stock over the term of the securities may negatively affect your return and will not
be offset or mitigated by any positive performance by the other underlying stocks. To receive
any
contingent monthly coupons,
all
of the underlying stocks must close at or above their respective downside threshold levels on
the applicable observation date. In addition, if
any
underlying stock has declined to below its respective downside threshold level as of the final
observation date, you will be
fully exposed
to
the decline in the worst performing underlying stock over the term of the securities on a 1-to-1 basis, even if the other underlying
stocks have appreciated or have not declined as much. Under this scenario, the value of any such payment will be less than 57.75%
of the stated principal amount and could be zero. Accordingly, your investment is subject to the price risk of all of the underlying
stocks.
|
|
§
|
The contingent coupon, if any, is based only on the determination closing prices of the underlying stocks on the related
monthly observation date at the end of the related interest period
.
Whether the contingent coupon will be paid on any coupon payment date will be determined at the end of the relevant interest period
based on the determination closing price of each underlying stock on the relevant monthly observation date. As a result, you will
not know whether you will receive the contingent coupon on any coupon payment date until near the end of the relevant interest
period. Moreover, because the contingent coupon is based solely on the price of each underlying stock on
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
monthly observation dates, if the
determination closing price of any underlying stock on any observation date is below the respective downside threshold level, you
will receive no coupon for the related interest period, or any previously unpaid coupons, even if the price(s) of one or more of
the underlying stocks were higher on other days during that interest period.
|
§
|
Investors will not participate in any appreciation in the price of any underlying stock.
Investors will not participate
in any appreciation in the price of any underlying stock from its initial share price, and the return on the securities will be
limited to the contingent monthly coupon, if any, that is paid with respect to each observation date on which all determination
closing prices are greater than or equal to their respective downside threshold levels, if any.
|
|
§
|
The market price will be influenced by many unpredictable factors.
Several factors, many of which are beyond our control, will influence the value of the securities
in the secondary market and the price at which MS & Co. may be willing to purchase or sell the securities in the secondary
market. We expect that generally the level of interest rates available in the market and the prices of the
underlying
stocks
on any day, including in relation to the respective
downside threshold levels, will affect the value of the securities more than any other factors. Other factors that may influence
the value of the securities include:
|
|
o
|
the trading price and volatility (frequency and magnitude of changes in value) of the underlying stocks,
|
|
o
|
whether the determination closing price of any underlying stock has been below its respective downside threshold level on any
observation date,
|
|
o
|
dividend rates on the underlying stocks,
|
|
o
|
geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underlying stocks
and which may affect the prices of the underlying stocks,
|
|
o
|
the time remaining until the securities mature,
|
|
o
|
interest and yield rates in the market,
|
|
o
|
the availability of comparable instruments,
|
|
o
|
the occurrence of certain events affecting the underlying stock that may or may not require an adjustment to the adjustment
factor, and
|
|
o
|
any actual or anticipated changes in our credit ratings or credit spreads.
|
Some
or all of these factors will influence the price that you will receive if you sell your securities prior to maturity. For example,
you may have to sell your securities at a substantial discount from the stated principal amount of $1,000 per security if the price
of any underlying stock at the time of sale is near or below its downside threshold level or if market interest rates rise.
The
prices of the underlying stocks may be, and have recently been, volatile, and we can give you no assurance that the volatility
will lessen.
The prices of the underlying stocks may decrease and be below the respective downside threshold level(s) on
each observation date so that you will receive no return on your investment and receive a payment at maturity that is less than
57.75% of the stated principal amount and could be zero. There can be no assurance that the determination closing prices of all
of the underlying stocks will be at or above their respective downside threshold levels on any observation date so that you will
receive a coupon payment on the securities for the applicable interest period, or, with respect to the final observation date,
so that you do no suffer a significant loss on your initial investment in the securities.
See
“CVS Health Corporation Overview,” “McDonald’s Corporation Overview,” “Johnson & Johnson
Overview” and “The Walt Disney Company Overview” below.
|
§
|
The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads
may adversely affect the market value of the securities.
You are dependent on our ability to pay all amounts due on the securities
on each coupon payment date, upon automatic redemption and at maturity and therefore you are subject to our credit risk. The securities
are not guaranteed by any other entity. If we default on our obligations under the securities, your investment would be at risk
and you could lose some or all of your investment. As a result,
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
the market value of the securities
prior to maturity will be affected by changes in the market’s view of our creditworthiness. Any actual or anticipated decline
in our credit ratings or increase in the credit spreads charged by the market for taking our credit risk is likely to adversely
affect the market value of the securities.
|
§
|
As a finance subsidiary, MSFL has no independent operations and will have no independent assets.
As a finance subsidiary,
MSFL has no independent operations beyond the issuance and administration of its securities and will have no independent assets
available for distributions to holders of MSFL securities if they make claims in respect of such securities in a bankruptcy, resolution
or similar proceeding. Accordingly, any recoveries by such holders will be limited to those available under the related guarantee
by Morgan Stanley and that guarantee will rank
pari passu
with all other unsecured, unsubordinated obligations of Morgan
Stanley. Holders will have recourse only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of
securities issued by MSFL should accordingly assume that in any such proceedings they would not have any priority over and should
be treated
pari passu
with the claims of other unsecured, unsubordinated creditors of Morgan Stanley, including holders
of Morgan Stanley-issued securities.
|
|
§
|
Reinvestment risk.
The term
of your investment in the securities may be shortened due to the automatic early redemption feature of the securities. If the securities
are redeemed prior to maturity, you will receive no more contingent monthly coupons and may be forced to invest in a lower interest
rate environment and may not be able to reinvest at comparable terms or returns. However, under no circumstances will the securities
be redeemed in the first six months of the term of the securities.
|
|
§
|
Investing in the securities is not equivalent to investing in the
common stock of CVS Health Corporation, the common stock of McDonald’s Corporation, the common stock of Johnson & Johnson
or the common stock of The Walt Disney Company.
Investors in the securities will not participate
in any appreciation in the underlying stocks, and will not have voting rights or rights to receive dividends or other distributions
or any other rights with respect to the underlying stocks. As a result, any return on the securities will not reflect the return
you would realize if you actually owned shares of the underlying stocks and received the dividends paid or distributions made on
them.
|
|
§
|
No affiliation with CVS Health Corporation, McDonald
’
s
Corporation,
Johnson & Johnson or The Walt Disney Company.
CVS Health Corporation, McDonald
’
s Corporation, Johnson &
Johnson and The Walt Disney Company are not affiliates of ours, are not involved with this offering in any way, and have no obligation
to consider your interests in taking any corporate actions that might affect the value of the securities. We have not made any
due diligence inquiry with respect to CVS Health Corporation, McDonald
’
s
Corporation, Johnson & Johnson or The Walt Disney Company in connection with this offering.
|
|
§
|
We may engage in business with or involving CVS Health Corporation, McDonald
’
s
Corporation, Johnson & Johnson or The Walt Disney Company without regard to your interests.
We or our affiliates may presently
or from time to time engage in business with CVS Health Corporation, McDonald
’
s
Corporation, Johnson & Johnson or The Walt Disney Company without regard to your interests and thus may acquire non-public
information about CVS Health Corporation, McDonald
’
s Corporation,
Johnson & Johnson or The Walt Disney Company. Neither we nor any of our affiliates undertakes to disclose any such information
to you. In addition, we or our affiliates from time to time have published and in the future may publish research reports with
respect to CVS Health Corporation, McDonald
’
s Corporation,
Johnson & Johnson or The Walt Disney Company, which may or may not recommend that investors buy or hold the underlying stock(s).
|
|
§
|
The antidilution adjustments the calculation agent is required to make do not cover every corporate event that could affect
the underlying stocks.
MS & Co., as calculation agent, will adjust the adjustment factors for certain corporate events
affecting the underlying stocks, such as stock splits, stock dividends and extraordinary dividends, and certain other corporate
actions involving the issuers of the underlying stocks, such as mergers. However, the calculation agent will not make an adjustment
for every corporate event that can affect the underlying stocks. For example, the calculation agent is not required to make any
adjustments if the issuers of the underlying stocks or anyone else makes a partial tender or partial exchange offer for the underlying
stocks, nor will adjustments be made following the final observation date. In addition, no adjustments will be made for regular
cash dividends, which are expected to reduce the price of the underlying stocks by the amount of such dividends
.
If an event occurs that does not require the
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
calculation agent to adjust an adjustment
factor, such as a regular cash dividend, the market price of the securities and your return on the securities may be materially
and adversely affected. For example, if the record date for a regular cash dividend were to occur on or shortly before an observation
date, this may decrease the determination closing price of an underlying stock to be less than the downside threshold level (resulting
in no contingent monthly coupon being paid with respect to such date) or the final share price of an underlying stock to be less
than the downside threshold level (resulting in a loss of a significant portion of all of your investment in the securities), materially
and adversely affecting your return.
|
§
|
The securities will not be listed on any securities exchange and secondary trading may be limited
,
and
accordingly, you should be willing to hold your securities for the entire 3-year term of the securities.
The
securities will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities.
MS & Co. may, but is not obligated to, make a market in the securities and, if it once chooses to make a market, may cease
doing so at any time. When it does make a market, it will generally do so for transactions of routine secondary market size at
prices based on its estimate of the current value of the securities, taking into account its bid/offer spread, our credit spreads,
market volatility, the notional size of the proposed sale, the cost of unwinding any related hedging positions, the time remaining
to maturity and the likelihood that it will be able to resell the securities. Even if there is a secondary market, it may not provide
enough liquidity to allow you to trade or sell the securities easily. Since other broker-dealers may not participate significantly
in the secondary market for the securities, the price at which you may be able to trade your securities is likely to depend on
the price, if any, at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease making a market in
the securities, it is likely that there would be no secondary market for the securities. Accordingly, you should be willing to
hold your securities to maturity.
|
|
§
|
The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate
implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated
with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities,
cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market
prices.
Assuming no change in market conditions or any other relevant factors, the prices, if any, at which dealers, including
MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly lower than
the original issue price, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs
that are included in the original issue price and borne by you and because the secondary market prices will reflect our secondary
market credit spreads and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well
as other factors.
|
The inclusion of the costs of issuing,
selling, structuring and hedging the securities in the original issue price and the lower rate we are willing to pay as issuer
make the economic terms of the securities less favorable to you than they otherwise would be.
However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 6 months
following the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes
in market conditions, including those related to the underlying stocks, and to our secondary market credit spreads, it would do
so based on values higher than the estimated value, and we expect that those higher values will also be reflected in your brokerage
account statements.
|
§
|
The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from
those of other dealers and is not a maximum or minimum secondary market price.
These pricing and valuation models are proprietary
and rely in part on subjective views of certain market inputs and certain assumptions about future events, which may prove to be
incorrect. As a result, because there is no market-standard way to value these types of securities, our models may yield a higher
estimated value of the securities than those generated by others, including other dealers in the market, if they attempted to value
the securities. In addition, the estimated value on the pricing date does not represent a minimum or maximum price at which dealers,
including MS & Co., would be willing to purchase your securities in the secondary market (if any exists) at any time. The value
of your securities at any time after the date of this document will vary based on many factors that cannot be predicted with
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
accuracy, including our creditworthiness
and changes in market conditions. See also “The market price will be influenced by many unpredictable factors” above.
|
§
|
Hedging and trading activity by our affiliates could potentially affect the value of the securities.
One or more of
our affiliates and/or third-party dealers expect to carry out hedging activities related to the securities (and to other instruments
linked to the underlying stocks), including trading in the underlying stocks. Some of our affiliates also trade the underlying
stocks and other financial instruments related to the underlying stocks on a regular basis as part of their general broker-dealer
and other businesses. As a result, these entities may be unwinding or adjusting hedge positions during the term of the securities,
and the hedging strategy may involve greater and more frequent dynamic adjustments to the hedge as the final observation date approaches.
Any of these hedging or trading activities on or prior to the pricing date could potentially increase the initial share price of
an underlying stock, and, therefore, could potentially increase (i) the value at or above which such underlying stock must close
on the redemption determination dates so that the securities are redeemed prior to maturity for the early redemption payment (depending
also on the performance of the other underlying stocks) and (ii) the downside threshold level for such underlying stock, which
is the value at or above which the underlying stock must close on the observation dates so that you receive a contingent monthly
coupon on the securities (depending also on the performance of the other underlying stocks), and, with respect to the final observation
date, so that you are not exposed to the negative performance of the worst performing underlying stock at maturity (depending also
on the performance of the other underlying stocks). Additionally, such hedging or trading activities during the term of the securities
could potentially affect the value of any underlying stock on the redemption determination dates and the observation dates, and,
accordingly, whether we redeem the securities prior to maturity, whether we pay a contingent monthly coupon on the securities and
the amount of cash you will receive at maturity, if any (depending also on the performance of the other underlying stocks).
|
|
§
|
The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect
to the securities.
As calculation agent, MS & Co. will determine the initial share prices, the redemption threshold levels,
the downside threshold levels, the final share prices, the payment at maturity, if any, whether you receive a contingent monthly
coupon on each coupon payment date and/or at maturity, whether the securities will be redeemed on any early redemption date, whether
a market disruption event has occurred and whether to make any adjustments to the adjustment factors. Moreover, certain determinations
made by MS & Co., in its capacity as calculation agent, may require it to exercise discretion and make subjective judgments,
such as with respect to the occurrence or non-occurrence of market disruption events and certain adjustments to the adjustment
factors. These potentially subjective determinations may affect the payout to you upon an automatic early redemption or at maturity,
if any. For further information regarding these types of determinations, see “Description of Auto-Callable Securities—Auto-Callable
Securities Linked to Underlying Shares” and “—Calculation Agent and Calculations” and related definitions
in the accompanying product supplement. In addition, MS & Co. has determined the estimated value of the securities on the pricing
date.
|
|
§
|
The U.S. federal income tax consequences of an investment in the securities are uncertain.
There is no direct legal
authority as to the proper treatment of the securities for U.S. federal income tax purposes, and, therefore, significant aspects
of the tax treatment of the securities are uncertain.
|
Please read the discussion under
“Additional Information—Tax considerations” in this document concerning the U.S. federal income tax consequences
of an investment in the securities. We intend to treat a security for U.S. federal income tax purposes as a single financial contract
that provides for a coupon that will be treated as gross income to you at the time received or accrued, in accordance with your
regular method of tax accounting. Under this treatment, the ordinary income treatment of the coupon payments, in conjunction with
the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could result in adverse
tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations. We do not
plan to request a ruling from the Internal Revenue Service (the “IRS”) regarding the tax treatment of the securities,
and the IRS or a court may not agree with the tax treatment described herein. If the IRS were successful in asserting an alternative
treatment for the securities, the timing and character of income or loss on the securities might differ significantly from the
tax treatment described herein. For example, under one possible treatment, the IRS could seek to recharacterize the securities
as debt instruments. In that event, U.S. Holders (as defined below) would be required to accrue into income original issue
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
discount on the securities every
year at a “comparable yield” determined at the time of issuance (as adjusted based on the difference, if any, between
the actual and the projected amount of any contingent payments on the securities) and recognize all income and gain in respect
of the securities as ordinary income. The risk that financial instruments providing for buffers, triggers or similar downside protection
features, such as the securities, would be recharacterized as debt is greater than the risk of recharacterization for comparable
financial instruments that do not have such features.
Non-U.S. Holders (as defined
below) should note that we currently intend to withhold on any coupon paid to Non-U.S. Holders generally at a rate of 30%, or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision, and will
not be required to pay any additional amounts with respect to amounts withheld.
In 2007, the U.S. Treasury Department
and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts”
and similar instruments. While it is not clear whether the securities would be viewed as similar to the prepaid forward contracts
described in the notice, it is possible that any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive
effect. The notice focuses on a number of issues, the most relevant of which for holders of the securities are the character and
timing of income or loss and the degree, if any, to which income realized by non-U.S. investors should be subject to withholding
tax. Both U.S. and Non-U.S. Holders should consult their tax advisers regarding the U.S. federal income tax consequences of an
investment in the securities, including possible alternative treatments, the issues presented by this notice and any tax consequences
arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
CVS Health Corporation
Overview
CVS Health Corporation is an integrated pharmacy health care
provider. The CVS Stock is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Information provided to or filed with the Securities and Exchange Commission by CVS Health Corporation pursuant to the Exchange
Act can be located by reference to the Securities and Exchange Commission file number 001-01011 through the Securities and Exchange
Commission’s website at www.sec.gov. In addition, information regarding CVS Health Corporation may be obtained from other
sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents.
Neither
the issuer nor the agent makes any representation that such publicly available documents or any other publicly available information
regarding the issuer of the CVS Stock is accurate or complete.
Information as of market close on July 11, 2019:
Bloomberg
Ticker Symbol:
|
CVS
|
Exchange:
|
NYSE
|
Current
Stock Price:
|
$57.97
|
52
Weeks Ago:
|
$67.30
|
52
Week High (on 11/13/2018):
|
$80.80
|
52
Week Low (on 4/2/2019):
|
$52.13
|
Current
Dividend Yield:
|
3.45%
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the CVS Stock for each quarter from January 1, 2016 through July 11, 2019.
The closing price of the CVS Stock on July 11, 2019 was $57.97. The associated graph shows the closing prices of the CVS Stock
for each day from January 1, 2014 through July 11, 2019. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the CVS Stock should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the CVS Stock at any time, including on the redemption
determination dates or the observation dates.
Common
Stock of CVS Health Corporation (CUSIP 126650100)
|
High
($)
|
Low
($)
|
Dividends
($)
|
2016
|
|
|
|
First Quarter
|
104.05
|
89.65
|
0.425
|
Second Quarter
|
106.10
|
93.21
|
0.425
|
Third Quarter
|
98.06
|
88.99
|
0.425
|
Fourth Quarter
|
88.80
|
73.53
|
0.50
|
2017
|
|
|
|
First Quarter
|
83.92
|
74.80
|
0.50
|
Second Quarter
|
82.79
|
75.95
|
0.50
|
Third Quarter
|
83.31
|
75.35
|
0.50
|
Fourth Quarter
|
80.91
|
66.80
|
0.50
|
2018
|
|
|
|
First Quarter
|
83.63
|
60.60
|
0.50
|
Second Quarter
|
72.18
|
60.71
|
0.50
|
Third Quarter
|
79.59
|
63.78
|
0.50
|
Fourth Quarter
|
80.80
|
62.92
|
0.50
|
2019
|
|
|
|
First Quarter
|
69.88
|
52.36
|
0.50
|
Second Quarter
|
57.33
|
52.13
|
0.50
|
Third Quarter (through July 11, 2019)
|
57.97
|
54.80
|
0.50
|
We make no representation as to the amount
of dividends, if any, that CVS Health Corporation may pay in the future. In any event, as an investor in the Contingent Income
Auto-Callable Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of CVS
Health Corporation.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Common Stock of
CVS Health Corporation – Daily Closing Prices
January 1, 2014 to July 11, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 57.75% of the initial share price, assuming the closing price of the underlying stock on July 11, 2019
were the initial share price.
This document relates only to the securities
offered hereby and does not relate to the CVS Stock or other securities of CVS Health Corporation. We have derived all disclosures
contained in this document regarding CVS Health Corporation stock from the publicly available documents described above. In connection
with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any
due diligence inquiry with respect to CVS Health Corporation. Neither we nor the agent makes any representation that such publicly
available documents or any other publicly available information regarding CVS Health Corporation is accurate or complete. Furthermore,
we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy
or completeness of the publicly available documents described above) that would affect the trading price of the CVS Stock (and
therefore the price of the CVS Stock at the time we price the securities) have been publicly disclosed. Subsequent disclosure of
any such events or the disclosure of or failure to disclose material future events concerning CVS Health Corporation could affect
the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates
makes any representation to you as to the performance of the CVS Stock.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
McDonald’s Corporation
Overview
McDonald’s Corporation operates and franchises McDonald’s
restaurants, which serve a locally relevant menu of food and beverages in more than 100 countries. The MCD Stock is registered
under the Exchange Act. Information provided to or filed with the Securities and Exchange Commission by McDonald
’
s
Corporation pursuant to the Exchange Act can be located by reference to the Securities and Exchange Commission file number 001-05231
through the Securities and Exchange Commission’s website at .www.sec.gov. In addition, information regarding McDonald
’
s
Corporation may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly
disseminated documents.
Neither the issuer nor the agent makes any representation that such publicly available documents or
any other publicly available information regarding the issuer of the MCD Stock is accurate or complete.
Information as of market close on July 11, 2019:
Bloomberg
Ticker Symbol:
|
MCD
|
Exchange:
|
NYSE
|
Current
Stock Price:
|
$212.69
|
52
Weeks Ago:
|
$158.62
|
52
Week High (on 7/10/2019):
|
$213.00
|
52
Week Low (on 8/2/2018):
|
$155.41
|
Current
Dividend Yield:
|
2.18%
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the MCD Stock for each quarter from January 1, 2016 through July 11, 2019.
The closing price of the MCD Stock on July 11, 2019 was $212.69. The associated graph shows the closing prices of the MCD Stock
for each day from January 1, 2014 through July 11, 2019. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the MCD Stock should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the MCD Stock at any time, including on the redemption
determination dates or the observation dates.
Common
Stock of McDonald’s Corporation (CUSIP 580135101)
|
High
($)
|
Low
($)
|
Dividends
($)
|
2016
|
|
|
|
First Quarter
|
125.83
|
115.12
|
0.89
|
Second Quarter
|
131.60
|
116.30
|
0.94
|
Third Quarter
|
128.26
|
114.44
|
0.94
|
Fourth Quarter
|
123.72
|
110.57
|
0.94
|
2017
|
|
|
|
First Quarter
|
129.61
|
119.48
|
0.94
|
Second Quarter
|
154.80
|
129.29
|
0.94
|
Third Quarter
|
161.53
|
151.85
|
0.94
|
Fourth Quarter
|
174.20
|
156.86
|
1.01
|
2018
|
|
|
|
First Quarter
|
178.36
|
148.27
|
1.01
|
Second Quarter
|
169.48
|
155.94
|
1.01
|
Third Quarter
|
167.29
|
155.41
|
1.01
|
Fourth Quarter
|
189.26
|
162.97
|
1.16
|
2019
|
|
|
|
First Quarter
|
189.90
|
173.97
|
1.16
|
Second Quarter
|
207.66
|
188.35
|
1.16
|
Third Quarter (through July 11, 2019)
|
213.00
|
206.30
|
-
|
We make no representation as to the amount
of dividends, if any, that McDonald
’
s Corporation may pay
in the future. In any event, as an investor in the Contingent Income Auto-Callable Securities, you will not be entitled to receive
dividends, if any, that may be payable on the common stock of McDonald
’
s
Corporation.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Common Stock of
McDonald
’
s Corporation – Daily Closing Prices
January 1, 2014 to July 11, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 57.75% of the initial share price, assuming the closing price of the underlying stock on July 11, 2019
were the initial share price.
This document relates only to the securities
offered hereby and does not relate to the MCD Stock or other securities of McDonald
’
s
Corporation. We have derived all disclosures contained in this document regarding McDonald
’
s
Corporation stock from the publicly available documents described above. In connection with the offering of the securities, neither
we nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect to McDonald
’
s
Corporation. Neither we nor the agent makes any representation that such publicly available documents or any other publicly available
information regarding McDonald
’
s Corporation is accurate or
complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that would
affect the accuracy or completeness of the publicly available documents described above) that would affect the trading price of
the MCD Stock (and therefore the price of the MCD Stock at the time we price the securities) have been publicly disclosed. Subsequent
disclosure of any such events or the disclosure of or failure to disclose material future events concerning McDonald
’
s
Corporation could affect the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates
makes any representation to you as to the performance of the MCD Stock.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Johnson & Johnson Overview
Johnson & Johnson is engaged in the research and development,
manufacture and sale of a range of products in the health-care field. The JNJ Stock is registered under the Exchange Act. Information
provided to or filed with the Securities and Exchange Commission by Johnson & Johnson pursuant to the Exchange Act can be located
by reference to the Securities and Exchange Commission file number 001-03215 through the Securities and Exchange Commission’s
website at .www.sec.gov. In addition, information regarding Johnson & Johnson may be obtained from other sources including,
but not limited to, press releases, newspaper articles and other publicly disseminated documents.
Neither the issuer nor the
agent makes any representation that such publicly available documents or any other publicly available information regarding the
issuer of the JNJ Stock is accurate or complete.
Information as of market close on July 11, 2019:
Bloomberg
Ticker Symbol:
|
JNJ
|
Exchange:
|
NYSE
|
Current
Stock Price:
|
$140.11
|
52
Weeks Ago:
|
$126.24
|
52
Week High (on 12/13/2018):
|
$147.84
|
52
Week Low (on 12/242018):
|
$122.84
|
Current
Dividend Yield:
|
2.71%
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the JNJ Stock for each quarter from January 1, 2016 through July 11, 2019.
The closing price of the JNJ Stock on July 11, 2019 was $140.11. The associated graph shows the closing prices of the JNJ Stock
for each day from January 1, 2014 through July 11, 2019. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the JNJ Stock should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the JNJ Stock at any time, including on the redemption
determination dates or the observation dates.
Common
Stock of Johnson & Johnson (CUSIP 478160104)
|
High
($)
|
Low($)
|
Dividends
($)
|
2016
|
|
|
|
First Quarter
|
109.14
|
95.75
|
0.75
|
Second Quarter
|
121.30
|
108.59
|
0.80
|
Third Quarter
|
125.40
|
117.27
|
0.80
|
Fourth Quarter
|
120.31
|
110.99
|
0.80
|
2017
|
|
|
|
First Quarter
|
128.96
|
111.76
|
0.80
|
Second Quarter
|
136.43
|
121.37
|
0.84
|
Third Quarter
|
136.57
|
129.47
|
0.84
|
Fourth Quarter
|
143.62
|
131.22
|
0.84
|
2018
|
|
|
|
First Quarter
|
148.14
|
125.10
|
0.84
|
Second Quarter
|
131.76
|
119.40
|
0.90
|
Third Quarter
|
142.88
|
121.58
|
0.90
|
Fourth Quarter
|
147.84
|
122.84
|
0.90
|
2019
|
|
|
|
First Quarter
|
139.79
|
125.72
|
0.90
|
Second Quarter
|
144.24
|
131.15
|
0.95
|
Third Quarter (through July 11, 2019)
|
142.14
|
139.36
|
-
|
We make no representation as to the amount
of dividends, if any, that Johnson & Johnson may pay in the future. In any event, as an investor in the Contingent Income Auto-Callable
Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of Johnson & Johnson.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Common Stock of
Johnson & Johnson – Daily Closing Prices
January 1, 2014 to July 11, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 57.75% of the initial share price, assuming the closing price of the underlying stock on July 11, 2019
were the initial share price.
This document relates only to the securities
offered hereby and does not relate to the JNJ Stock or other securities of Johnson & Johnson. We have derived all disclosures
contained in this document regarding Johnson & Johnson stock from the publicly available documents described above. In connection
with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any
due diligence inquiry with respect to Johnson & Johnson. Neither we nor the agent makes any representation that such publicly
available documents or any other publicly available information regarding Johnson & Johnson is accurate or complete. Furthermore,
we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy
or completeness of the publicly available documents described above) that would affect the trading price of the JNJ Stock (and
therefore the price of the JNJ Stock at the time we price the securities) have been publicly disclosed. Subsequent disclosure of
any such events or the disclosure of or failure to disclose material future events concerning Johnson & Johnson could affect
the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of
its affiliates makes any representation to you as to the performance of the JNJ Stock.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
The Walt Disney Company Overview
The Walt Disney Company is a diversified worldwide entertainment
company. The DIS Stock is registered under the Exchange Act. Information provided to or filed with the Securities and Exchange
Commission by The Walt Disney Company. pursuant to the Exchange Act can be located by reference to the Securities and Exchange
Commission file number 001-11605 through the Securities and Exchange Commission’s website at .www.sec.gov. In addition, information
regarding The Walt Disney Company may be obtained from other sources including, but not limited to, press releases, newspaper articles
and other publicly disseminated documents.
Neither the issuer nor the agent makes any representation that such publicly available
documents or any other publicly available information regarding the issuer of the DIS Stock is accurate or complete.
Information as of market close on July 11, 2019:
Bloomberg
Ticker Symbol:
|
DIS
|
Exchange:
|
NYSE
|
Current
Stock Price:
|
$143.56
|
52
Weeks Ago:
|
$108.04
|
52
Week High (on 7/11/2019):
|
$143.56
|
52
Week Low (on 12/24/2018):
|
$100.35
|
Current
Dividend Yield:
|
1.23%
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the DIS Stock for each quarter from January 1, 2016 through July 11, 2019.
The closing price of the DIS Stock on July 11, 2019 was $143.56. The associated graph shows the closing prices of the DIS Stock
for each day from January 1, 2014 through July 11, 2019. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the DIS Stock should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the DIS Stock at any time, including on the redemption
determination dates or the observation dates.
Common
Stock of The Walt Disney Company (CUSIP 254687106)
|
High
($)
|
Low($)
|
Dividends
($)
|
2016
|
|
|
|
First Quarter
|
102.98
|
88.85
|
-
|
Second Quarter
|
106.60
|
94.38
|
0.71
|
Third Quarter
|
100.20
|
91.72
|
-
|
Fourth Quarter
|
105.56
|
90.83
|
0.78
|
2017
|
|
|
|
First Quarter
|
113.39
|
106.08
|
-
|
Second Quarter
|
115.84
|
103.94
|
0.78
|
Third Quarter
|
110.61
|
97.06
|
-
|
Fourth Quarter
|
111.81
|
96.93
|
0.84
|
2018
|
|
|
|
First Quarter
|
112.47
|
98.54
|
-
|
Second Quarter
|
108.85
|
98.66
|
0.84
|
Third Quarter
|
116.94
|
104.04
|
-
|
Fourth Quarter
|
118.90
|
100.35
|
0.88
|
2019
|
|
|
|
First Quarter
|
115.25
|
106.33
|
-
|
Second Quarter
|
142.02
|
111.96
|
0.88
|
Third Quarter (through July 11, 2019)
|
143.56
|
141.02
|
-
|
We make no representation as to the amount
of dividends, if any, that The Walt Disney Company may pay in the future. In any event, as an investor in the Contingent Income
Auto-Callable Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of The
Walt Disney Company.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Common Stock of
The Walt Disney Company – Daily Closing Prices
January 1, 2014 to July 11, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 57.75% of the initial share price, assuming the closing price of the underlying stock on July 11, 2019
were the initial share price.
This document relates only to the securities
offered hereby and does not relate to the DIS Stock or other securities of The Walt Disney Company. We have derived all disclosures
contained in this document regarding The Walt Disney Company stock from the publicly available documents described above. In connection
with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any
due diligence inquiry with respect to The Walt Disney Company. Neither we nor the agent makes any representation that such publicly
available documents or any other publicly available information regarding The Walt Disney Company is accurate or complete. Furthermore,
we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy
or completeness of the publicly available documents described above) that would affect the trading price of the DIS Stock (and
therefore the price of the DIS Stock at the time we price the securities) have been publicly disclosed. Subsequent disclosure of
any such events or the disclosure of or failure to disclose material future events concerning The Walt Disney Company could affect
the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates makes any representation
to you as to the performance of the DIS Stock.
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Additional Terms of the Securities
Please read this information in conjunction with the summary
terms on the front cover of this document.
Additional
Terms:
|
If the terms described herein are inconsistent with those described in the accompanying product supplement or prospectus, the terms described herein shall control.
|
Interest
period:
|
The monthly period from and including the original issue date (in the case of the first interest period) or the previous scheduled coupon payment date, as applicable, to but excluding the following scheduled coupon payment date, with no adjustment for any postponement thereof.
|
Record
date:
|
The record date for each coupon payment date shall be the date one business day prior to such scheduled coupon payment date;
provided
, however, that any coupon payable at maturity (or upon early redemption) shall be payable to the person to whom the payment at maturity or early redemption payment, as the case may be, shall be payable.
|
Underlying
stock:
|
The accompanying product supplement refers to the underlying stock as the “underlying shares.”
|
Underlying
stock issuer:
|
With respect to the CVS Stock, CVS Health Corporation
With respect to the MCD Stock, McDonald
’
s
Corporation
With respect to the JNJ Stock, Johnson & Johnson
With respect to the DIS Stock, The Walt Disney Company
The accompanying product supplement refers to each underlying
stock issuer as an “underlying company.”
|
Downside
threshold level:
|
The accompanying product supplement refers to the downside threshold level as the “trigger level.”
|
Day
count convention:
|
Interest will be computed on the basis of a 360-day year of twelve 30-day months.
|
Postponement of maturity date:
|
If the final observation date is postponed due to a non-trading day or certain market disruption events with respect to any underlying stock so that it falls less than two business days prior to the scheduled maturity date, the maturity date will be postponed to the second business day following that final observation date as postponed with respect to any underlying stock, and no adjustment will be made to the payment at maturity made on that postponed date.
|
Antidilution
adjustments:
|
The following replaces in its entirety the portion of the
section entitled “Antidilution Adjustments” in the accompanying product supplement for auto-callable securities from
the start of paragraph 5 to the end of such section.
5. If, with respect to one or more of the underlying stocks,
(i) there occurs any reclassification or change of such underlying stock, including, without limitation, as a result of the issuance
of any tracking stock by the underlying stock issuer for such underlying stock, (ii) such underlying stock issuer or any surviving
entity or subsequent surviving entity of such underlying stock issuer (the “successor corporation”) has been subject
to a merger, combination or consolidation and is not the surviving entity, (iii) any statutory exchange of securities of such underlying
stock issuer or any successor corporation with another corporation occurs (other than pursuant to clause (ii) above), (iv) such
underlying stock issuer is liquidated, (v) such underlying stock issuer issues to all of its shareholders equity securities of
an issuer other than such underlying stock issuer (other than in a transaction described in clause (ii), (iii) or (iv) above) (a
“spin-off event”) or (vi) a tender or exchange offer or going-private transaction is consummated for all the outstanding
shares of such underlying stock (any such event in clauses (i) through (vi), a “reorganization event”), the method
of determining whether an early redemption has occurred and the amount payable upon an early redemption date or at maturity for
each security will be as follows:
·
Upon
any redemption determination date following the effective date of a reorganization event and prior to the final observation date:
If the exchange property value (as defined below) is greater than or equal to the respective redemption threshold level, and the
determination closing price (or exchange property value, if applicable) of each other underlying stock is also greater than or
equal to its redemption threshold level, the securities will be automatically redeemed for an early redemption payment.
·
Upon the final observation date, if the securities have not previously
been automatically redeemed: You will receive for each security that you hold a payment at maturity equal
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
to:
Ø
If
the exchange property value on the final observation date is greater than or equal to the respective downside threshold level,
and the final share price of each other underlying stock (or exchange property value, as applicable) is also greater than its respective
downside threshold level:
(i) the stated principal amount plus (ii) the contingent monthly coupon with respect to the final
observation date and any previously unpaid contingent monthly coupons from the prior observation dates.
Ø
If
the exchange property value on the final observation date is less than the respective downside threshold level, or if the final
share price (or exchange property value, if applicable) of any other underlying stock is less than its respective downside threshold
level:
Ø
If
the worst performing underlying stock has not undergone a reorganization event as described in paragraph 5 above:
(i) the stated
principal amount multiplied by (ii) the share performance factor of the worst performing underlying stock.
Ø
If
the worst performing underlying stock has undergone a reorganization event as described in paragraph 5 above:
(i) the stated
principal amount multiplied by (ii) the share performance factor of the worst performing underlying stock. For purposes of determining
the share performance factor of the worst performing underlying stock, the final share price of such worst performing underlying
stock will be deemed to equal the per-share cash value, determined as of the final observation date, of the securities, cash or
any other assets distributed to holders of the worst performing underlying stock in or as a result of any such reorganization event,
including (A) in the case of the issuance of tracking stock, the reclassified share of such worst performing underlying stock,
(B) in the case of a spin-off event, the share of such worst performing underlying stock with respect to which the spun-off security
was issued, and (C) in the case of any other reorganization event where such worst performing underlying stock continues to be
held by the holders receiving such distribution, such worst performing underlying stock (collectively, the “exchange property”).
Following the effective date of a reorganization event, the contingent
monthly coupon, as well as any previously unpaid contingent monthly coupons, will be payable for each observation date on which
the exchange property value is greater than or equal to the downside threshold level and the determination closing price (or exchange
property value, as applicable) of each other underlying stock is also greater than or equal to its downside threshold level.
If exchange property includes a cash component,
investors will not receive any interest accrued on such cash component. In the event exchange property consists of securities,
those securities will, in turn, be subject to the antidilution adjustments set forth in paragraphs 1 through 5.
For purposes of determining whether or not
the exchange property value is less than the initial share price, or less than the downside threshold level, or for determining
the worst performing underlying stock, “exchange property value” means (x) for any cash received in any reorganization
event, the value, as determined by the calculation agent, as of the date of receipt, of such cash received for one share of such
underlying stock, as adjusted by the adjustment factor at the time of such reorganization event, (y) for any property other than
cash or securities received in any such reorganization event, the market value, as determined by the calculation agent in its sole
discretion, as of the date of receipt, of such exchange property received for one share of such underlying stock, as adjusted by
the adjustment factor at the time of such reorganization event and (z) for any security received in any such reorganization event,
an amount equal to the determination closing price, as of the day on which the exchange property value is determined, per share
of such security multiplied by the quantity of such security received for each share of such underlying stock, as adjusted by the
adjustment factor at the time of such reorganization event.
For purposes of paragraph 5 above, in the case
of a consummated tender or exchange offer or going-private transaction involving consideration of particular types, exchange property
shall be deemed to include the amount of cash or other property delivered by the offeror in the tender or exchange offer (in an
amount determined on the basis of the rate of exchange in such tender or exchange offer or going-private transaction). In the event
of a tender or exchange offer or a going-private transaction with respect to exchange property in which an
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
offeree may elect to receive cash or other
property, exchange property shall be deemed to include the kind and amount of cash and other property received by offerees who
elect to receive cash.
Following the occurrence of any reorganization
event referred to in paragraph 5 above, all references in this offering document and in the related product supplement with respect
to the securities to such “underlying stock” shall be deemed to refer to the exchange property and references to a
“share” or “shares” of such underlying stock shall be deemed to refer to the applicable unit or units of
such exchange property, unless the context otherwise requires.
No adjustment to the adjustment factor will
be required unless such adjustment would require a change of at least 0.1% in the adjustment factor then in effect. The adjustment
factor resulting from any of the adjustments specified above will be rounded to the nearest one hundred-thousandth, with five one-millionths
rounded upward. Adjustments to the adjustment factor will be made up to the close of business on the final observation date.
No adjustments to the adjustment factor or
method of calculating the adjustment factor will be required other than those specified above. The adjustments specified above
do not cover all events that could affect the determination closing price or the final share price of such underlying stock, including,
without limitation, a partial tender or exchange offer for such underlying stock.
The calculation agent shall be solely responsible
for the determination and calculation of any adjustments to the adjustment factor or method of calculating the adjustment factor
and of any related determinations and calculations with respect to any distributions of stock, other securities or other property
or assets (including cash) in connection with any corporate event described in paragraphs 1 through 5 above, and its determinations
and calculations with respect thereto shall be conclusive in the absence of manifest error.
The calculation agent will provide information as to any adjustments
to the adjustment factor or to the method of calculating the amount payable at maturity of the securities made pursuant to paragraph
5 above upon written request by any investor in the securities.
|
Trustee:
|
The Bank of New York Mellon
|
Calculation
agent:
|
MS & Co.
|
Issuer
notices to registered security holders, the trustee and the depositary:
|
In the event that the maturity date is postponed due to postponement
of the final observation date, the issuer shall give notice of such postponement and, once it has been determined, of the date
to which the maturity date has been rescheduled (i) to each registered holder of the securities by mailing notice of such postponement
by first class mail, postage prepaid, to such registered holder’s last address as it shall appear upon the registry books,
(ii) to the trustee by facsimile, confirmed by mailing such notice to the trustee by first class mail, postage prepaid, at its
New York office and (iii) to The Depository Trust Company (the “depositary”) by telephone or facsimile confirmed by
mailing such notice to the depositary by first class mail, postage prepaid. Any notice that is mailed to a registered holder of
the securities in the manner herein provided shall be conclusively presumed to have been duly given to such registered holder,
whether or not such registered holder receives the notice. The issuer shall give such notice as promptly as possible, and in no
case later than (i) with respect to notice of postponement of the maturity date, the business day immediately preceding the scheduled
maturity date and (ii) with respect to notice of the date to which the maturity date has been rescheduled, the business day immediately
following the final observation date as postponed.
In the event that the securities are subject to early redemption,
the issuer shall, (i) on the business day following the applicable redemption determination date, give notice of the early redemption
and the early redemption payment, including specifying the payment date of the amount due upon the early redemption, (x) to each
registered holder of the securities by mailing notice of such early redemption by first class mail, postage prepaid, to such registered
holder’s last address as it shall appear upon the registry books, (y) to the trustee by facsimile confirmed by mailing such
notice to the trustee by first class mail, postage prepaid, at its New York office and (z) to the depositary by telephone or facsimile
confirmed by mailing such notice to the depositary by first class mail, postage prepaid, and (ii) on or prior to the early redemption
date, deliver the aggregate cash amount due with respect to the securities to the trustee for delivery to the depositary, as holder
of the securities. Any notice that is mailed to a registered holder of the securities in the manner herein provided shall be conclusively
presumed to have been duly given to such registered holder, whether or not such registered
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
holder receives the notice. This notice shall be given by the
issuer or, at the issuer’s request, by the trustee in the name and at the expense of the issuer, with any such request to
be accompanied by a copy of the notice to be given.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash to be delivered as contingent monthly coupon, if any, with respect to each security on or prior to 10:30 a.m. (New York City
time) on the business day preceding each coupon payment date, and (ii) deliver the aggregate cash amount due, if any, with respect
to the contingent monthly coupon to the trustee for delivery to the depositary, as holder of the securities, on the applicable
coupon payment date.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash, if any, to be delivered with respect to the securities, on or prior to 10:30 a.m. (New York City time) on the business day
preceding the maturity date, and (ii) deliver the aggregate cash amount due with respect to the securities, if any, to the trustee
for delivery to the depositary, as holder of the securities, on the maturity date.
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
Additional Information About the Securities
Additional
Information:
|
Minimum
ticketing size:
|
$1,000 / 1 security
|
Tax considerations:
|
Prospective investors should note that the discussion under
the section called “United States Federal Taxation” in the accompanying product supplement does not apply to the securities
issued under this document and is superseded by the following discussion.
The following is a general discussion of the material U.S. federal
income tax consequences and certain estate tax consequences of the ownership and disposition of the securities. This discussion
applies only to investors in the securities who:
·
purchase
the securities in the original offering; and
·
hold
the securities as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the “Code”).
This discussion does not describe all of the
tax consequences that may be relevant to a holder in light of the holder’s particular circumstances or to holders subject
to special rules, such as:
·
certain
financial institutions;
·
insurance
companies;
·
certain
dealers and traders in securities or commodities;
·
investors
holding the securities as part of a “straddle,” wash sale, conversion transaction, integrated transaction or constructive
sale transaction;
·
U.S.
Holders (as defined below) whose functional currency is not the U.S. dollar;
·
partnerships
or other entities classified as partnerships for U.S. federal income tax purposes;
·
regulated
investment companies;
·
real
estate investment trusts; or
·
tax-exempt
entities, including “individual retirement accounts” or “Roth IRAs” as defined in Section 408 or 408A of
the Code, respectively.
If an entity that is classified as a partnership
for U.S. federal income tax purposes holds the securities, the U.S. federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. If you are a partnership holding the securities or a partner
in such a partnership, you should consult your tax adviser as to the particular U.S. federal tax consequences of holding and disposing
of the securities to you.
As the law applicable to the U.S. federal income
taxation of instruments such as the securities is technical and complex, the discussion below necessarily represents only a general
summary. The effect of any applicable state, local or non-U.S. tax laws is not discussed, nor are any alternative minimum tax consequences
or consequences resulting from the Medicare tax on investment income. Moreover, the discussion below does not address the consequences
to taxpayers subject to special tax accounting rules under Section 451(b) of the Code.
This discussion is based on the Code, administrative
pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, all as of the date hereof, changes to
any of which subsequent to the date hereof may affect the tax consequences described herein. Persons considering the purchase of
the securities should consult their tax advisers with regard to the application of the U.S. federal income tax laws to their particular
situations as well as any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
General
Due to the absence of statutory, judicial or administrative authorities
that directly address the
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
treatment of the securities or instruments
that are similar to the securities for U.S. federal income tax purposes, no assurance can be given that the IRS or a court will
agree with the tax treatment described herein. We intend to treat a security for U.S. federal income tax purposes as a single financial
contract that provides for a coupon that will be treated as gross income to you at the time received or accrued in accordance with
your regular method of tax accounting. In the opinion of our counsel, Davis Polk & Wardwell LLP, this treatment of the securities
is reasonable under current law; however, our counsel has advised us that it is unable to conclude affirmatively that this treatment
is more likely than not to be upheld, and that alternative treatments are possible. Moreover, our counsel’s opinion is based
on market conditions as of the date of this preliminary pricing supplement and is subject to confirmation on the pricing date.
You should consult your tax adviser regarding
all aspects of the U.S. federal tax consequences of an investment in the securities (including possible alternative treatments
of the securities). Unless otherwise stated, the following discussion is based on the treatment of each security as described in
the previous paragraph.
Tax Consequences to U.S. Holders
This section applies to you only if you are
a U.S. Holder. As used herein, the term “U.S. Holder” means a beneficial owner of a security that is, for U.S. federal
income tax purposes:
·
a
citizen or individual resident of the United States;
·
a
corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state
thereof or the District of Columbia; or
·
an
estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
Tax Treatment of the Securities
Assuming the treatment of the securities as
set forth above is respected, the following U.S. federal income tax consequences should result.
Tax Basis
. A U.S. Holder’s tax
basis in the securities should equal the amount paid by the U.S. Holder to acquire the securities.
Tax Treatment of Coupon Payments
.
Any coupon payment on the securities should be taxable as ordinary income to a U.S. Holder at the time received or accrued, in
accordance with the U.S. Holder’s regular method of accounting for U.S. federal income tax purposes.
Sale,
Exchange or Settlement of the Securities
. Upon a sale, exchange or settlement of the securities, a U.S. Holder should recognize
gain or loss equal to the difference between the amount realized on the sale, exchange or settlement and the U.S. Holder’s
tax basis in the securities sold, exchanged or settled. For this purpose, the amount realized does not include any coupon paid
at settlement and may not include sale proceeds attributable to an accrued coupon, which may be treated as a coupon payment. Any
such gain or loss recognized should be long-term capital gain or loss if the U.S. Holder has held the securities for more than
one year at the time of the sale, exchange or settlement, and should be short-term capital gain or loss otherwise. The ordinary
income treatment of the coupon payments, in conjunction with the capital loss treatment of any loss recognized upon the sale,
exchange or settlement of the securities, could result in adverse tax consequences to holders of the securities because the deductibility
of capital losses is subject to limitations.
Possible Alternative Tax Treatments of an Investment in
the Securities
Due to the absence of authorities that directly
address the proper tax treatment of the securities, no assurance can be given that the IRS will accept, or that a court will uphold,
the treatment described above. In particular, the IRS could seek to analyze the U.S. federal income tax consequences of owning
the securities under Treasury regulations governing
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
contingent payment debt instruments (the “Contingent Debt
Regulations”). If the IRS were successful in asserting that the Contingent Debt Regulations applied to the securities, the
timing and character of income thereon would be significantly affected. Among other things, a U.S. Holder would be required to
accrue into income original issue discount on the securities every year at a “comparable yield” determined at the time
of their issuance, adjusted upward or downward to reflect the difference, if any, between the actual and the projected amount of
any contingent payments on the securities. Furthermore, any gain realized by a U.S. Holder at maturity or upon a sale, exchange
or other disposition of the securities would be treated as ordinary income, and any loss realized would be treated as ordinary
loss to the extent of the U.S. Holder’s prior accruals of original issue discount and as capital loss thereafter. The risk
that financial instruments providing for buffers, triggers or similar downside protection features, such as the securities, would
be recharacterized as debt is greater than the risk of recharacterization for comparable financial instruments that do not have
such features.
Other alternative federal income tax treatments of the securities
are possible, which, if applied, could significantly affect the timing and character of the income or loss with respect to the
securities. In 2007, the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal income
tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses on whether to require holders
of “prepaid forward contracts” and similar instruments to accrue income over the term of their investment. It also
asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; whether
short-term instruments should be subject to any such accrual regime; the relevance of factors such as the exchange–traded
status of the instruments and the nature of the underlying property to which the instruments are linked; whether these instruments
are or should be subject to the “constructive ownership” rule, which very generally can operate to recharacterize certain
long-term capital gain as ordinary income and impose an interest charge; and appropriate transition rules and effective dates.
While it is not clear whether instruments such as the securities would be viewed as similar to the prepaid forward contracts described
in the notice, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and
adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect. U.S. Holders should
consult their tax advisers regarding the U.S. federal income tax consequences of an investment in the securities, including possible
alternative treatments and the issues presented by this notice.
Backup Withholding and Information Reporting
Backup withholding may apply in respect of payments on the securities
and the payment of proceeds from a sale, exchange or other disposition of the securities, unless a U.S. Holder provides proof of
an applicable exemption or a correct taxpayer identification number and otherwise complies with applicable requirements of the
backup withholding rules. The amounts withheld under the backup withholding rules are not an additional tax and may be refunded,
or credited against the U.S. Holder’s U.S. federal income tax liability, provided that the required information is timely
furnished to the IRS. In addition, information returns will be filed with the IRS in connection with payments on the securities
and the payment of proceeds from a sale, exchange or other disposition of the securities, unless the U.S. Holder provides proof
of an applicable exemption from the information reporting rules.
Tax Consequences to Non-U.S. Holders
This section applies to you only if you are a Non-U.S. Holder.
As used herein, the term “Non-U.S. Holder” means a beneficial owner of a security that is for U.S. federal income tax
purposes:
·
an
individual who is classified as a nonresident alien;
·
a
foreign corporation; or
·
a
foreign estate or trust.
The term “Non-U.S. Holder” does
not include any of the following holders:
·
a
holder who is an individual present in the United States for 183 days or more in the taxable year of disposition and who is not
otherwise a resident of the
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
United States for U.S. federal income
tax purposes;
·
certain
former citizens or residents of the United States; or
·
a
holder for whom income or gain in respect of the securities is effectively connected with the conduct of a trade or business in
the United States.
Such holders should consult their tax advisers regarding the
U.S. federal income tax consequences of an investment in the securities.
Although significant aspects of the tax treatment of each security
are uncertain, we intend to withhold on any coupon paid to a Non-U.S. Holder generally at a rate of 30% or at a reduced rate specified
by an applicable income tax treaty under an “other income” or similar provision. We will not be required to pay any
additional amounts with respect to amounts withheld. In order to claim an exemption from, or a reduction in, the 30% withholding
tax, a Non-U.S. Holder of the securities must comply with certification requirements to establish that it is not a U.S. person
and is eligible for such an exemption or reduction under an applicable tax treaty. If you are a Non-U.S. Holder, you should consult
your tax adviser regarding the tax treatment of the securities, including the possibility of obtaining a refund of any withholding
tax and the certification requirement described above.
Section 871(m) Withholding Tax on Dividend Equivalents
Section 871(m) of the Code and Treasury regulations promulgated
thereunder (“Section 871(m)”) generally impose a 30% (or a lower applicable treaty rate) withholding tax on dividend
equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities or indices
that include U.S. equities (each, an “Underlying Security”). Subject to certain exceptions, Section 871(m) generally
applies to securities that substantially replicate the economic performance of one or more Underlying Securities, as determined
based on tests set forth in the applicable Treasury regulations (a “Specified Security”). However, pursuant to an IRS
notice, Section 871(m) will not apply to securities issued before January 1, 2021 that do not have a delta of one with respect
to any Underlying Security. Based on the terms of the securities and current market conditions, we expect that the securities will
not have a delta of one with respect to any Underlying Security on the pricing date. However, we will provide an updated determination
in the pricing supplement. Assuming that the securities do not have a delta of one with respect to any Underlying Security, our
counsel is of the opinion that the securities should not be Specified Securities and, therefore, should not be subject to Section
871(m).
Our determination is not binding on the IRS, and the IRS may
disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including
whether you enter into other transactions with respect to an Underlying Security. If Section 871(m) withholding is required, we
will not be required to pay any additional amounts with respect to the amounts so withheld. You should consult your tax adviser
regarding the potential application of Section 871(m) to the securities.
U.S. Federal Estate Tax
Individual Non-U.S. Holders and entities the property of which
is potentially includible in such an individual’s gross estate for U.S. federal estate tax purposes (for example, a trust
funded by such an individual and with respect to which the individual has retained certain interests or powers) should note that,
absent an applicable treaty exemption, the securities may be treated as U.S.-situs property subject to U.S. federal estate tax.
Prospective investors that are non-U.S. individuals, or are entities of the type described above, should consult their tax advisers
regarding the U.S. federal estate tax consequences of an investment in the securities.
Backup Withholding and Information Reporting
Information returns will be filed with the IRS in connection
with any coupon payment and may be filed with the IRS in connection with the payment at maturity on the securities and the payment
of proceeds from a sale, exchange or other disposition. A Non-U.S. Holder may be subject to backup withholding in respect of amounts
paid to the Non-U.S. Holder, unless such
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
Non-U.S. Holder complies with certification procedures to establish
that it is not a U.S. person for U.S. federal income tax purposes or otherwise establishes an exemption. The amount of any backup
withholding from a payment to a Non-U.S. Holder will be allowed as a credit against the Non-U.S. Holder’s U.S. federal income
tax liability and may entitle the Non-U.S. Holder to a refund, provided that the required information is timely furnished to the
IRS.
FATCA
Legislation commonly referred to as “FATCA” generally
imposes a withholding tax of 30% on payments to certain non-U.S. entities (including financial intermediaries) with respect to
certain financial instruments, unless various U.S. information reporting and due diligence requirements have been satisfied. An
intergovernmental agreement between the United States and the non-U.S. entity’s jurisdiction may modify these requirements.
FATCA generally applies to certain financial instruments that are treated as paying U.S.-source interest or other U.S.-source “fixed
or determinable annual or periodical” income (“FDAP income”). Withholding (if applicable) applies to payments
of U.S.-source FDAP income and to payments of gross proceeds of the disposition (including upon retirement) of certain financial
instruments treated as providing for U.S.-source interest or dividends. Under recently proposed regulations (the preamble to which
specifies that taxpayers are permitted to rely on them pending finalization), no withholding will apply on payments of gross proceeds
(other than amounts treated as FDAP income). While the treatment of the securities is unclear, you should assume that any coupon
payment with respect to the securities will be subject to the FATCA rules. If withholding applies to the securities, we will not
be required to pay any additional amounts with respect to amounts withheld. Both U.S. and Non-U.S. Holders should consult their
tax advisers regarding the potential application of FATCA to the securities.
The discussion in the preceding paragraphs,
insofar as it purports to describe provisions of U.S. federal income tax laws or legal conclusions with respect thereto, constitutes
the full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of an investment in the
securities.
|
Use
of proceeds and hedging:
|
The proceeds from the sale of the securities will be used by
us for general corporate purposes. We will receive, in aggregate, $1,000 per security issued, because, when we enter into hedging
transactions in order to meet our obligations under the securities, our hedging counterparty will reimburse the cost of the agent’s
commissions. The costs of the securities borne by you and described beginning on page 3 above comprise the agent’s commissions
and the cost of issuing, structuring and hedging the securities.
On or prior to the pricing date, we expect to hedge our anticipated
exposure in connection with the securities by entering into hedging transactions with our affiliates and/or third-party dealers.
We expect our hedging counterparties to take positions in the underlying stocks, in futures and/or options contracts on the underlying
stocks, or positions in any other available securities or instruments that they may wish to use in connection with such hedging.
Such purchase activity could potentially increase the initial share price of an underlying stock, and, therefore, could potentially
increase (i) the value at or above which such underlying stock must close on the redemption determination dates so that the securities
are redeemed prior to maturity for the early redemption payment (depending also on the performance of the other underlying stocks)
and (ii) the downside threshold level for such underlying stock, which is the value at or above which the underlying stock must
close on the observation dates so that you receive a contingent monthly coupon on the securities (depending also on the performance
of the other underlying stocks), and, with respect to the final observation date, so that you are not exposed to the negative performance
of the underlying stock at maturity (depending also on the performance of the other underlying stocks). These entities may be unwinding
or adjusting hedge positions during the term of the securities, and the hedging strategy may involve greater and more frequent
dynamic adjustments to the hedge as the final observation date approaches. Additionally, our hedging activities, as well as our
other trading activities, during the term of the securities could potentially affect the value of any underlying stock on the redemption
determination dates and other observation dates, and, accordingly, whether we redeem the securities prior to maturity, whether
we pay a contingent monthly coupon on the securities and the amount of cash you will receive at maturity, if any (depending also
on the performance of the other underlying stocks). For further information on our use of proceeds and hedging, see “Use
of Proceeds and Hedging” in the accompanying product supplement.
|
Benefit plan investor considerations:
|
Each fiduciary of a pension, profit-sharing or other employee
benefit plan subject to Title I of
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (a “Plan”),
should consider the fiduciary standards of ERISA in the context of the Plan’s particular circumstances before authorizing
an investment in the securities. Accordingly, among other factors, the fiduciary should consider whether the investment would satisfy
the prudence and diversification requirements of ERISA and would be consistent with the documents and instruments governing the
Plan.
In addition, we and certain of our affiliates, including MS &
Co., may each be considered a “party in interest” within the meaning of ERISA, or a “disqualified person”
within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”), with respect to many Plans, as well
as many individual retirement accounts and Keogh plans (such accounts and plans, together with other plans, accounts and arrangements
subject to Section 4975 of the Code, also “Plans”). ERISA Section 406 and Code Section 4975 generally prohibit transactions
between Plans and parties in interest or disqualified persons. Prohibited transactions within the meaning of ERISA or the Code
would likely arise, for example, if the securities are acquired by or with the assets of a Plan with respect to which MS &
Co. or any of its affiliates is a service provider or other party in interest, unless the securities are acquired pursuant to an
exemption from the “prohibited transaction” rules. A violation of these “prohibited transaction” rules
could result in an excise tax or other liabilities under ERISA and/or Section 4975 of the Code for those persons, unless exemptive
relief is available under an applicable statutory or administrative exemption.
The U.S. Department of Labor has issued five prohibited transaction
class exemptions (“PTCEs”) that may provide exemptive relief for direct or indirect prohibited transactions resulting
from the purchase or holding of the securities. Those class exemptions are PTCE 96-23 (for certain transactions determined by in-house
asset managers), PTCE 95-60 (for certain transactions involving insurance company general accounts), PTCE 91-38 (for certain transactions
involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company separate accounts)
and PTCE 84-14 (for certain transactions determined by independent qualified professional asset managers). In addition, ERISA Section
408(b)(17) and Code Section 4975(d)(20) provide an exemption for the purchase and sale of securities and the related lending transactions,
provided that neither the issuer of the securities nor any of its affiliates has or exercises any discretionary authority or control
or renders any investment advice with respect to the assets of the Plan involved in the transaction and provided further that the
Plan pays no more, and receives no less, than “adequate consideration” in connection with the transaction (the so-called
“service provider” exemption). There can be no assurance that any of these class or statutory exemptions will be available
with respect to transactions involving the securities.
Because we may be considered a party in interest with respect
to many Plans, the securities may not be purchased, held or disposed of by any Plan, any entity whose underlying assets include
“plan assets” by reason of any Plan’s investment in the entity (a “Plan Asset Entity”) or any person
investing “plan assets” of any Plan, unless such purchase, holding or disposition is eligible for exemptive relief,
including relief available under PTCEs 96-23, 95-60, 91-38, 90-1, 84-14 or the service provider exemption or such purchase, holding
or disposition is otherwise not prohibited. Any purchaser, including any fiduciary purchasing on behalf of a Plan, transferee or
holder of the securities will be deemed to have represented, in its corporate and its fiduciary capacity, by its purchase and holding
of the securities that either (a) it is not a Plan or a Plan Asset Entity and is not purchasing such securities on behalf of or
with “plan assets” of any Plan or with any assets of a governmental, non-U.S. or church plan that is subject to any
federal, state, local or non-U.S. law that is substantially similar to the provisions of Section 406 of ERISA or Section 4975 of
the Code (“Similar Law”) or (b) its purchase, holding and disposition of these securities will not constitute or result
in a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Code or violate any Similar Law.
Due to the complexity of these rules and the penalties that may
be imposed upon persons involved in non-exempt prohibited transactions, it is particularly important that fiduciaries or other
persons considering purchasing the securities on behalf of or with “plan assets” of any Plan consult with their counsel
regarding the availability of exemptive relief.
The securities are contractual financial instruments. The financial
exposure provided by the securities is not a substitute or proxy for, and is not intended as a substitute or proxy for, individualized
investment management or advice for the benefit of any purchaser or holder of the securities. The securities have not been designed
and will not be administered in a
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
manner intended to reflect the individualized needs and objectives
of any purchaser or holder of the securities.
Each purchaser or holder of any securities acknowledges and agrees
that:
(i)
the
purchaser or holder or its fiduciary has made and shall make all investment decisions for the purchaser or holder and the purchaser
or holder has not relied and shall not rely in any way upon us or our affiliates to act as a fiduciary or adviser of the purchaser
or holder with respect to (A) the design and terms of the securities, (B) the purchaser or holder’s investment in the securities,
or (C) the exercise of or failure to exercise any rights we have under or with respect to the securities;
(ii)
we
and our affiliates have acted and will act solely for our own account in connection with (A) all transactions relating to the securities
and (B) all hedging transactions in connection with our obligations under the securities;
(iii)
any
and all assets and positions relating to hedging transactions by us or our affiliates are assets and positions of those entities
and are not assets and positions held for the benefit of the purchaser or holder;
(iv)
our
interests are adverse to the interests of the purchaser or holder; and
(v)
neither
we nor any of our affiliates is a fiduciary or adviser of the purchaser or holder in connection with any such assets, positions
or transactions, and any information that we or any of our affiliates may provide is not intended to be impartial investment advice.
Each purchaser and holder of the securities has exclusive responsibility
for ensuring that its purchase, holding and disposition of the securities do not violate the prohibited transaction rules of ERISA
or the Code or any Similar Law. The sale of any securities to any Plan or plan subject to Similar Law is in no respect a representation
by us or any of our affiliates or representatives that such an investment meets all relevant legal requirements with respect to
investments by plans generally or any particular plan, or that such an investment is appropriate for plans generally or any particular
plan. In this regard, neither this discussion nor anything provided in this document is or is intended to be investment advice
directed at any potential Plan purchaser or at Plan purchasers generally and such purchasers of these securities should consult
and rely on their own counsel and advisers as to whether an investment in these securities is suitable.
However, individual retirement accounts, individual retirement
annuities and Keogh plans, as well as employee benefit plans that permit participants to direct the investment of their accounts,
will not be permitted to purchase or hold the securities if the account, plan or annuity is for the benefit of an employee of Morgan
Stanley or Morgan Stanley Wealth Management or a family member and the employee receives any compensation (such as, for example,
an addition to bonus) based on the purchase of the securities by the account, plan or annuity.
|
Additional considerations:
|
Client accounts over which Morgan Stanley, Morgan Stanley Wealth Management or any of their respective subsidiaries have investment discretion are
not
permitted to purchase the securities, either directly or indirectly.
|
Supplemental information regarding
plan of distribution; conflicts of interest:
|
Selected dealers, which may include our affiliates, and their
financial advisors will collectively receive from the agent a fixed sales commission of $ for each security they sell.
MS & Co. is an affiliate of MSFL and a wholly owned subsidiary
of Morgan Stanley, and it and other affiliates of ours expect to make a profit by selling, structuring and, when applicable, hedging
the securities. When MS & Co. prices this offering of securities, it will determine the economic terms of the securities such
that for each security the estimated value on the pricing date will be no lower than the minimum level described in “Investment
Summary” beginning on page 3.
MS & Co. will conduct this offering in compliance with the
requirements of FINRA Rule 5121 of the Financial Industry Regulatory Authority, Inc., which is commonly referred to as FINRA, regarding
a FINRA member firm’s distribution of the securities of an affiliate and related conflicts of interest. MS & Co. or any
of our other affiliates may not make sales in this offering to any discretionary account. See “Plan of Distribution (Conflicts
of Interest)” and “Use of Proceeds and Hedging” in the accompanying product supplement for auto-callable securities.
|
Where
you can find more information:
|
MSFL and Morgan Stanley have filed a registration statement (including
a prospectus, as
|
Morgan Stanley Finance LLC
Contingent Income
Auto-Callable Securities due July 28, 2022, with 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of CVS Health Corporation, the Common Stock of McDonald’s Corporation, the Common Stock of Johnson & Johnson and the Common Stock of The Walt Disney Company
Principal at Risk Securities
|
supplemented by the product supplement for auto-callable securities)
with the Securities and Exchange Commission, or SEC, for the offering to which this communication relates. You should read the
prospectus in that registration statement, the product supplement for auto-callable securities and any other documents relating
to this offering that MSFL and Morgan Stanley have filed with the SEC for more complete information about MSFL, Morgan Stanley
and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at
.
www.sec.gov.
Alternatively, MSFL, Morgan Stanley, any underwriter or any dealer participating in the offering will arrange to send you the prospectus
and the product supplement for auto-callable securities if you so request by calling toll-free 1-(800)-584-6837.
You may access these documents on the SEC web site at
.
www.sec.gov
as follows:
Product Supplement for Auto-Callable Securities dated November 16, 2017
Prospectus dated November 16, 2017
Terms used but not defined in this document are defined in the
product supplement for auto-callable securities or in the prospectus.
|
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024